semaglutide fda approval history Approves Oral as the First Oral GLP-1 Pill A big win for Wegovy:

Regulatory Status Orforglipron (Foundayo) : FDA approved on April 1, 2026, for chronic weight management in adults with obesity or overweight with at least one weight-related condition

The acronym MASH characterizes MASLD accompanied by steatohepatitis, and cryptogenic SLD defines SLD in people without cardiometabolic risk factors and without a known etiology for liver disease [15]

Lets take a closer look at Semaglutide and how our programs can help you achieve your 2025 goals

Similarly, someone with bulimia nervosa could misuse a GLP-1 in the same way they might turn to self-induced vomiting, laxatives, or excessive exercise to compensate for binge eating behaviors

Or would we rather, you know, sell now to somebody with greater know how greater marketing, you know, because truthfully, and I know, you know, this, and youve written about this in your book, but like, when youre dealing with a supply chain crisis, you know, the ship that everybody had to deal with in the last two years with China, and overseas shipping